Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes ( <scp>LIRA‐SWITCH</scp> ): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial

Abstract

Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.